An open-label, non-randomized, multicenter, two-stage, phase 2 study of S-1 in chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer.

Trial Profile

An open-label, non-randomized, multicenter, two-stage, phase 2 study of S-1 in chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 24 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Planned End Date changed from 1 Nov 2009 to 1 Oct 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top